IGKV1-5 antibody

Catalog No. ABIN7115198

Product Details anti-IGKV1-5 Antibody

Target: IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This IGKV1-5 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Purification: Immunogen affinity purified

Purity: ≥95 % as determined by SDS-PAGE

Immunogen: immunoglobulin kappa variable 1-5

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:2000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: -20°C for 12 months (Avoid repeated freeze / thaw cycles.)

Expiry Date: 12 months

Target Details for IGKV1-5

Target: IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

Alternative Name: IGKV1-5 (IGKV1-5 Products)

Synonyms: IGKV antibody, IGKV15 antibody, L12 antibody, L12a antibody, V1 antibody, immunoglobulin kappa variable 1-5 antibody, IGKV1-5 antibody

Background: Synonyms: Background:V segment of the variable domain of immunoglobulins light chain that participates to the antigen recognition. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens(PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen(PubMed:20176268, PubMed:17576170).

UniProt: P01602